EUVIMEDEUVIMED entdecken
Crossref

Synthesis and Evaluation of 99m Tc-Labeled D Pro-Gly-Containing Tracers Targeting PSMA

Zuojie Li, Yuhao Jiang, Qing Ruan iD, Guangxing Yin, Peiwen Han, Xiaojiang Duan, Junbo Zhang iD

Molecular Pharmaceutics · 07.10.2024 · 21 (10) · 5305-5314

DOI: 10.1021/acs.molpharmaceut.4c00799 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 19.09.2024. Verfasst von Zuojie Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Radiopharmaceuticals of the Ministry of Education, College of Chemistry, NMPA Key Laboratory for Research and Evaluation of Radioph…. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Radiopharmaceuticals, Glutamate Carboxypeptidase II, Technetium. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Natural Science Foundation of Beijing Municipality, National Natural Science Foundation of China, Beijing Nova Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The specific expression of prostate-specific membrane antigen (PSMA) makes it an ideal target for the diagnosis and treatment of prostate cancer. Currently, many 99mTc-labeled PSMA-targeted tracers have been developed. However, the high renal uptake of these 99mTc-labeled tracers is a common problem that limits their clinical application. In this work, the ligand (EUKPG) using DPro-Gly as the linker was synthesized and three 99mTc-labeled complexes ([99mTc]Tc-EUKPG-EDDA, [99mTc]Tc-EUKPG-TPPTS, [99mTc]Tc-EUKPG-TPPMS) with different coligands were prepared and evaluated. Among them, [99mTc]Tc-EUKPG-EDDA showed the most favorable pharmacokinetic properties, with significantly reduced uptake in the kidney (14.04 ± 0.23% ID/g), rapid clearance and low uptake in nontarget organs, thus making it to exhibit high tumor-to-background ratios (tumor/blood: 7.47, tumor/muscle: 12.65). Affinity studies have shown that it has high specificity for PSMA both in vivo and in vitro. Therefore, [99mTc]Tc-EUKPG-EDDA has great potential as a promising molecular tracer to target PSMA for tumor imaging.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsRadiopharmaceuticalsGlutamate Carboxypeptidase IITechnetiumAntigens, SurfaceMaleAnimalsMiceHumansTissue DistributionOrganotechnetium CompoundsCell Line, TumorLigands

Stichwörter der Autor:innen

99mTcPSMASPECTtracertumor

Substanzen

RadiopharmaceuticalsGlutamate Carboxypeptidase IITechnetiumAntigens, SurfaceFOLH1 protein, humanOrganotechnetium CompoundsLigands

Autor:innen und Institutionen

  • Key Laboratory of Radiopharmaceuticals of the Ministry of Education, College of Chemistry, NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Beijing Norm…
  • Key Laboratory of Beam Technology of the Ministry of Education, College of Physics and Astronomy, Beijing Normal University, Beijing 100875, P. R. China.
  • Department of Nuclear Medicine, Peking University First Hospital, Beijing 100034, P. R. China.

ORCID-Profile: Qing Ruan, Junbo Zhang

Förderung

  • Natural Science Foundation of Beijing Municipality
  • National Natural Science Foundation of China
  • Beijing Nova Program

Zitieren

APA

Li, Z., Jiang, Y., Ruan, Q., Yin, G., Han, P., Duan, X., & Zhang, J. (2024). Synthesis and Evaluation of 99m Tc-Labeled D Pro-Gly-Containing Tracers Targeting PSMA. Molecular Pharmaceutics, 21(10), 5305-5314. https://doi.org/10.1021/acs.molpharmaceut.4c00799

Vancouver

Li Z, Jiang Y, Ruan Q, Yin G, Han P, Duan X, et al. Synthesis and Evaluation of 99m Tc-Labeled D Pro-Gly-Containing Tracers Targeting PSMA. Molecular Pharmaceutics. 2024;21(10):5305-5314. doi:10.1021/acs.molpharmaceut.4c00799

BibTeX
@article{Li2024,
  author = {Li, Zuojie and Jiang, Yuhao and Ruan, Qing and Yin, Guangxing and Han, Peiwen and Duan, Xiaojiang and Zhang, Junbo},
  title = {Synthesis and Evaluation of 99m Tc-Labeled D Pro-Gly-Containing Tracers Targeting PSMA},
  journal = {Molecular Pharmaceutics},
  year = {2024},
  volume = {21},
  number = {10},
  pages = {5305--5314},
  doi = {10.1021/acs.molpharmaceut.4c00799}
}
Kostenlos starten →